These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 33225826)

  • 1. Cordycepin: a bioactive metabolite of C
    Verma AK
    J Biomol Struct Dyn; 2022 May; 40(8):3745-3752. PubMed ID: 33225826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
    Verma AK; Aggarwal R
    Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp).
    Bibi S; Hasan MM; Wang YB; Papadakos SP; Yu H
    Curr Med Chem; 2022; 29(1):152-162. PubMed ID: 34420502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication.
    Rabie AM
    ACS Omega; 2022 Jan; 7(3):2960-2969. PubMed ID: 35071937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
    Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
    Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19.
    Mujwar S; Sun L; Fidan O
    J Food Biochem; 2022 Sep; 46(9):e14219. PubMed ID: 35545850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic
    Ashraf SA; Elkhalifa AEO; Siddiqui AJ; Patel M; Awadelkareem AM; Snoussi M; Ashraf MS; Adnan M; Hadi S
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32545666
    [No Abstract]   [Full Text] [Related]  

  • 9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
    Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
    J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
    Abdurrahman L; Fang X; Zhang Y
    Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Pandey AK; Verma S
    Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision therapeutic targets for COVID-19.
    Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
    Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
    Toor HG; Banerjee DI; Lipsa Rath S; Darji SA
    Eur J Pharmacol; 2021 Jan; 890():173720. PubMed ID: 33160938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach.
    Ambrose JM; Kullappan M; Patil S; Alzahrani KJ; Banjer HJ; Qashqari FSI; Raj AT; Bhandi S; Veeraraghavan VP; Jayaraman S; Sekar D; Agarwal A; Swapnavahini K; Krishna Mohan S
    Molecules; 2022 Mar; 27(6):. PubMed ID: 35335139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.
    Maffucci I; Contini A
    J Proteome Res; 2020 Nov; 19(11):4637-4648. PubMed ID: 32893632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.